Regen BioPharma Inc (RGBP)

[OTCShotCaller]

Here's something that hasn't been mentioned that needs to be said

IF the source of the $50M funding for this Triangular Acquisition is a Big Pharma (BP), it will represent a strategic move on several levels:

#1- first shot at developing any of Regen's IPs

#2- diversification into Precision Oncology: presently a $168B Global Market projected to skyrocket to $280B by 2028. This represents Disruptive Biotechnology that will define the future of ALL cancer diagnosis & treatment methods keeping in mind that the BP will own Canary via a Reverse Acquisition (i.e. a private company acquired by a public company).

#3- breaking into the mRNA Cancer Vaccine Market via Regen's NR2F6 IP.

#4- An indirect working relationship with Weill-Cornell that functions in part for fast tracking Big Pharma IPs to commercialization (see #2 Link below). This is in-sync with their rapid acceleration of therapeutics "Bench-to-Bedside" directive by harnessing innovative scientific approaches including artificial intelligence, translational cellular therapy, regenerative medicine, etc. Canary fits right into this directive with its Precision Oncology Diagnostic Platform. (see links below a MUST READ!)

https://news.weill.cornell.edu/news/2021/09/ready-to-launch-weill-cornell-has-an-ambitious-new-plan-to-change-medicine-0

(Weill-Cornell Partnerships with Big Pharmas to speed drug discovery)
https://news.weill.cornell.edu/news/2012/06/weill-cornell-partners-with-pharmaceutical-companies-and-academic-researchers-to-speed-tuberculosis

An important directive of ALL BPs is Market Diversification & Dominance that places them ahead of their fierce competition. This is what Gilead Sciences did when they acquired Kite Pharma in 2017 for $12B motivated in part by Kite's mRNA Cancer Vaccine IP when little was known about mRNA Vaccines at that time.

In regard to this, it's interesting to note that 2017 was the general time frame when Eli Lilly paid $100M to partner with Curevac to develop an mRNA Cancer Vaccine that failed in 2020 due to Curevac's faulty research data. I'm willing to bet Lilly is going to re-attempt this pursuit that might land them back in partnership with Regen. After all they have had prior collaborative arrangements with Regen on the NR2F6 IP they hold partial claim on that's the basis for an mRNA Cancer Vaccine. Is it making sense yet??

The BP that acquires Canary will have in-direct partnership with Regen due to owning its subsidiary. There are many advantages to this arrangement, i.e. additional funding for IP development, etc.

Like I've said before, Koos is an absolute genius and I believe he's going to make good on this Acquisition. Why? It was brilliantly planned with key players and innovative Biotechnology combined!

Lastly, I don't see any reason why this Acquisition won't be funded for reason there are vast strategic Market implications for any Big Pharma that springs for the $50M keeping in mind that this amount of money to ANY BP is "chump change" relative to their typical Multi-Billion Market Cap. i.e. Gilead Sciences $86B, Eli Lilly $226B.

OPINION ONLY

All feedback welcome with your personal perspectives.

Be well and prosper...